nodes	percent_of_prediction	percent_of_DWPC	metapath
Pemetrexed—SLC29A1—pancreatic cancer	0.349	0.737	CbGaD
Pemetrexed—TYMS—pancreatic cancer	0.124	0.263	CbGaD
Pemetrexed—SLC29A1—Gemcitabine—pancreatic cancer	0.0809	0.222	CbGbCtD
Pemetrexed—DCK—Gemcitabine—pancreatic cancer	0.075	0.206	CbGbCtD
Pemetrexed—TYMS—Gemcitabine—pancreatic cancer	0.075	0.206	CbGbCtD
Pemetrexed—SLC29A1—Fluorouracil—pancreatic cancer	0.0692	0.19	CbGbCtD
Pemetrexed—TYMS—Fluorouracil—pancreatic cancer	0.0641	0.176	CbGbCtD
Pemetrexed—GART—islet of Langerhans—pancreatic cancer	0.00191	0.164	CbGeAlD
Pemetrexed—GART—pancreas—pancreatic cancer	0.00134	0.115	CbGeAlD
Pemetrexed—GART—digestive system—pancreatic cancer	0.00114	0.0986	CbGeAlD
Pemetrexed—Raltitrexed—TYMS—pancreatic cancer	0.00097	0.351	CrCbGaD
Pemetrexed—SLC46A1—digestive system—pancreatic cancer	0.000929	0.0801	CbGeAlD
Pemetrexed—ATIC—pancreas—pancreatic cancer	0.00091	0.0784	CbGeAlD
Pemetrexed—SLC29A1—islet of Langerhans—pancreatic cancer	0.000787	0.0679	CbGeAlD
Pemetrexed—ATIC—digestive system—pancreatic cancer	0.000777	0.067	CbGeAlD
Pemetrexed—DCK—islet of Langerhans—pancreatic cancer	0.000752	0.0648	CbGeAlD
Pemetrexed—Leucovorin—TYMS—pancreatic cancer	0.000735	0.266	CrCbGaD
Pemetrexed—Pralatrexate—TYMS—pancreatic cancer	0.000735	0.266	CrCbGaD
Pemetrexed—DCK—Topotecan—Irinotecan—pancreatic cancer	0.000711	0.341	CbGdCrCtD
Pemetrexed—SLC29A1—pancreas—pancreatic cancer	0.000553	0.0477	CbGeAlD
Pemetrexed—DCK—pancreas—pancreatic cancer	0.000529	0.0456	CbGeAlD
Pemetrexed—TYMS—digestive system—pancreatic cancer	0.000527	0.0454	CbGeAlD
Pemetrexed—DHFR—digestive system—pancreatic cancer	0.000522	0.045	CbGeAlD
Pemetrexed—SLC29A1—digestive system—pancreatic cancer	0.000473	0.0407	CbGeAlD
Pemetrexed—DCK—digestive system—pancreatic cancer	0.000451	0.0389	CbGeAlD
Pemetrexed—TYMS—Paclitaxel—Docetaxel—pancreatic cancer	0.000376	0.18	CbGdCrCtD
Pemetrexed—TYMS—Gefitinib—Erlotinib—pancreatic cancer	0.00036	0.173	CbGdCrCtD
Pemetrexed—Methotrexate—TYMS—pancreatic cancer	0.000324	0.117	CrCbGaD
Pemetrexed—DCK—Clomifene—Tamoxifen—pancreatic cancer	0.000219	0.105	CbGdCrCtD
Pemetrexed—DCK—Doxorubicin—Epirubicin—pancreatic cancer	0.000167	0.0802	CbGdCrCtD
Pemetrexed—DCK—Epirubicin—Doxorubicin—pancreatic cancer	0.000155	0.0742	CbGdCrCtD
Pemetrexed—TYMS—Azacitidine—Gemcitabine—pancreatic cancer	9.73e-05	0.0467	CbGdCrCtD
Pemetrexed—TYMS—G1/S Transition—RB1—pancreatic cancer	7.51e-05	0.00169	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—BRCA2—pancreatic cancer	7.43e-05	0.00167	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—DTX4—pancreatic cancer	7.43e-05	0.00167	CbGpPWpGaD
Pemetrexed—Erythema multiforme—Docetaxel—pancreatic cancer	7.38e-05	0.000727	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle, Mitotic—PPP2R5B—pancreatic cancer	7.37e-05	0.00166	CbGpPWpGaD
Pemetrexed—Anorexia—Fluorouracil—pancreatic cancer	7.33e-05	0.000722	CcSEcCtD
Pemetrexed—Eye disorder—Docetaxel—pancreatic cancer	7.3e-05	0.000719	CcSEcCtD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—RB1—pancreatic cancer	7.25e-05	0.00163	CbGpPWpGaD
Pemetrexed—Vomiting—Tamoxifen—pancreatic cancer	7.23e-05	0.000712	CcSEcCtD
Pemetrexed—SLC46A1—Disease—PPP2R5B—pancreatic cancer	7.22e-05	0.00163	CbGpPWpGaD
Pemetrexed—Mood swings—Epirubicin—pancreatic cancer	7.21e-05	0.00071	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—SMAD4—pancreatic cancer	7.2e-05	0.00162	CbGpPWpGaD
Pemetrexed—Cerebrovascular accident—Doxorubicin—pancreatic cancer	7.19e-05	0.000708	CcSEcCtD
Pemetrexed—Hypersensitivity—Sunitinib—pancreatic cancer	7.18e-05	0.000707	CcSEcCtD
Pemetrexed—Rash—Tamoxifen—pancreatic cancer	7.17e-05	0.000706	CcSEcCtD
Pemetrexed—Dermatitis—Tamoxifen—pancreatic cancer	7.17e-05	0.000706	CcSEcCtD
Pemetrexed—Vomiting—Erlotinib—pancreatic cancer	7.16e-05	0.000705	CcSEcCtD
Pemetrexed—Dyspnoea—Irinotecan—pancreatic cancer	7.16e-05	0.000705	CcSEcCtD
Pemetrexed—Blood creatinine increased—Epirubicin—pancreatic cancer	7.13e-05	0.000702	CcSEcCtD
Pemetrexed—DHFR—Folate Metabolism—TNF—pancreatic cancer	7.13e-05	0.0016	CbGpPWpGaD
Pemetrexed—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	7.12e-05	0.000701	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—ARG2—pancreatic cancer	7.11e-05	0.0016	CbGpPWpGaD
Pemetrexed—Rash—Erlotinib—pancreatic cancer	7.1e-05	0.000699	CcSEcCtD
Pemetrexed—Dermatitis—Erlotinib—pancreatic cancer	7.09e-05	0.000698	CcSEcCtD
Pemetrexed—Dehydration—Epirubicin—pancreatic cancer	7.08e-05	0.000697	CcSEcCtD
Pemetrexed—Dyspepsia—Irinotecan—pancreatic cancer	7.07e-05	0.000696	CcSEcCtD
Pemetrexed—DHFR—E2F transcription factor network—MYC—pancreatic cancer	7.06e-05	0.00159	CbGpPWpGaD
Pemetrexed—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	7e-05	0.00069	CcSEcCtD
Pemetrexed—Asthenia—Sunitinib—pancreatic cancer	6.99e-05	0.000688	CcSEcCtD
Pemetrexed—Decreased appetite—Irinotecan—pancreatic cancer	6.98e-05	0.000687	CcSEcCtD
Pemetrexed—Arrhythmia—Docetaxel—pancreatic cancer	6.98e-05	0.000687	CcSEcCtD
Pemetrexed—Dyspnoea—Gemcitabine—pancreatic cancer	6.97e-05	0.000686	CcSEcCtD
Pemetrexed—SLC46A1—Disease—HEY2—pancreatic cancer	6.95e-05	0.00156	CbGpPWpGaD
Pemetrexed—Gastrointestinal disorder—Irinotecan—pancreatic cancer	6.93e-05	0.000682	CcSEcCtD
Pemetrexed—Fatigue—Irinotecan—pancreatic cancer	6.92e-05	0.000681	CcSEcCtD
Pemetrexed—Alopecia—Docetaxel—pancreatic cancer	6.9e-05	0.00068	CcSEcCtD
Pemetrexed—Pruritus—Sunitinib—pancreatic cancer	6.89e-05	0.000679	CcSEcCtD
Pemetrexed—Pain—Irinotecan—pancreatic cancer	6.86e-05	0.000676	CcSEcCtD
Pemetrexed—Constipation—Irinotecan—pancreatic cancer	6.86e-05	0.000676	CcSEcCtD
Pemetrexed—Aspartate aminotransferase increased—Epirubicin—pancreatic cancer	6.86e-05	0.000675	CcSEcCtD
Pemetrexed—Toxic epidermal necrolysis—Epirubicin—pancreatic cancer	6.86e-05	0.000675	CcSEcCtD
Pemetrexed—Dyspnoea—Fluorouracil—pancreatic cancer	6.85e-05	0.000675	CcSEcCtD
Pemetrexed—Erythema—Docetaxel—pancreatic cancer	6.8e-05	0.000669	CcSEcCtD
Pemetrexed—Malnutrition—Docetaxel—pancreatic cancer	6.8e-05	0.000669	CcSEcCtD
Pemetrexed—Decreased appetite—Gemcitabine—pancreatic cancer	6.8e-05	0.000669	CcSEcCtD
Pemetrexed—Dyspepsia—Fluorouracil—pancreatic cancer	6.77e-05	0.000666	CcSEcCtD
Pemetrexed—Nausea—Tamoxifen—pancreatic cancer	6.76e-05	0.000665	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Gemcitabine—pancreatic cancer	6.75e-05	0.000665	CcSEcCtD
Pemetrexed—Fatigue—Gemcitabine—pancreatic cancer	6.74e-05	0.000664	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—FOXM1—pancreatic cancer	6.73e-05	0.00151	CbGpPWpGaD
Pemetrexed—Alanine aminotransferase increased—Epirubicin—pancreatic cancer	6.72e-05	0.000661	CcSEcCtD
Pemetrexed—GART—Metabolism—CD44—pancreatic cancer	6.71e-05	0.00151	CbGpPWpGaD
Pemetrexed—Constipation—Gemcitabine—pancreatic cancer	6.69e-05	0.000658	CcSEcCtD
Pemetrexed—Pain—Gemcitabine—pancreatic cancer	6.69e-05	0.000658	CcSEcCtD
Pemetrexed—Nausea—Erlotinib—pancreatic cancer	6.69e-05	0.000658	CcSEcCtD
Pemetrexed—Decreased appetite—Fluorouracil—pancreatic cancer	6.68e-05	0.000658	CcSEcCtD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—CCND1—pancreatic cancer	6.68e-05	0.0015	CbGpPWpGaD
Pemetrexed—Mood swings—Doxorubicin—pancreatic cancer	6.67e-05	0.000657	CcSEcCtD
Pemetrexed—Diarrhoea—Sunitinib—pancreatic cancer	6.67e-05	0.000657	CcSEcCtD
Pemetrexed—Dysgeusia—Docetaxel—pancreatic cancer	6.66e-05	0.000656	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Fluorouracil—pancreatic cancer	6.64e-05	0.000654	CcSEcCtD
Pemetrexed—Blood creatinine increased—Doxorubicin—pancreatic cancer	6.6e-05	0.00065	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle—PPP2R5B—pancreatic cancer	6.59e-05	0.00148	CbGpPWpGaD
Pemetrexed—Dysphagia—Epirubicin—pancreatic cancer	6.58e-05	0.000648	CcSEcCtD
Pemetrexed—Pain—Fluorouracil—pancreatic cancer	6.57e-05	0.000647	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle, Mitotic—FOXM1—pancreatic cancer	6.57e-05	0.00148	CbGpPWpGaD
Pemetrexed—Gastrointestinal pain—Irinotecan—pancreatic cancer	6.56e-05	0.000646	CcSEcCtD
Pemetrexed—Dehydration—Doxorubicin—pancreatic cancer	6.55e-05	0.000645	CcSEcCtD
Pemetrexed—Pancreatitis—Epirubicin—pancreatic cancer	6.45e-05	0.000635	CcSEcCtD
Pemetrexed—Dizziness—Sunitinib—pancreatic cancer	6.44e-05	0.000635	CcSEcCtD
Pemetrexed—SLC46A1—Disease—HEY1—pancreatic cancer	6.44e-05	0.00145	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—GLP1R—pancreatic cancer	6.43e-05	0.00145	CbGpPWpGaD
Pemetrexed—GART—Metabolism—GCG—pancreatic cancer	6.43e-05	0.00145	CbGpPWpGaD
Pemetrexed—Angina pectoris—Epirubicin—pancreatic cancer	6.41e-05	0.000631	CcSEcCtD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—CDKN2A—pancreatic cancer	6.37e-05	0.00143	CbGpPWpGaD
Pemetrexed—Abdominal pain—Irinotecan—pancreatic cancer	6.34e-05	0.000625	CcSEcCtD
Pemetrexed—Body temperature increased—Irinotecan—pancreatic cancer	6.34e-05	0.000625	CcSEcCtD
Pemetrexed—Toxic epidermal necrolysis—Doxorubicin—pancreatic cancer	6.34e-05	0.000625	CcSEcCtD
Pemetrexed—Aspartate aminotransferase increased—Doxorubicin—pancreatic cancer	6.34e-05	0.000625	CcSEcCtD
Pemetrexed—ATIC—Metabolism—DPYD—pancreatic cancer	6.33e-05	0.00142	CbGpPWpGaD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—RB1—pancreatic cancer	6.33e-05	0.00142	CbGpPWpGaD
Pemetrexed—DHFR—Folate Metabolism—TP53—pancreatic cancer	6.29e-05	0.00141	CbGpPWpGaD
Pemetrexed—Anaemia—Docetaxel—pancreatic cancer	6.28e-05	0.000619	CcSEcCtD
Pemetrexed—DCK—Retinoblastoma (RB) in Cancer—TP53—pancreatic cancer	6.27e-05	0.00141	CbGpPWpGaD
Pemetrexed—Pancytopenia—Epirubicin—pancreatic cancer	6.25e-05	0.000615	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—TYMP—pancreatic cancer	6.22e-05	0.0014	CbGpPWpGaD
Pemetrexed—Alanine aminotransferase increased—Doxorubicin—pancreatic cancer	6.21e-05	0.000612	CcSEcCtD
Pemetrexed—Vomiting—Sunitinib—pancreatic cancer	6.2e-05	0.00061	CcSEcCtD
Pemetrexed—Body temperature increased—Gemcitabine—pancreatic cancer	6.18e-05	0.000609	CcSEcCtD
Pemetrexed—TYMS—E2F transcription factor network—MYC—pancreatic cancer	6.16e-05	0.00139	CbGpPWpGaD
Pemetrexed—Neutropenia—Epirubicin—pancreatic cancer	6.15e-05	0.000606	CcSEcCtD
Pemetrexed—Rash—Sunitinib—pancreatic cancer	6.14e-05	0.000605	CcSEcCtD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—MYC—pancreatic cancer	6.14e-05	0.00138	CbGpPWpGaD
Pemetrexed—Dermatitis—Sunitinib—pancreatic cancer	6.14e-05	0.000604	CcSEcCtD
Pemetrexed—Urticaria—Fluorouracil—pancreatic cancer	6.11e-05	0.000601	CcSEcCtD
Pemetrexed—Syncope—Docetaxel—pancreatic cancer	6.1e-05	0.0006	CcSEcCtD
Pemetrexed—Dysphagia—Doxorubicin—pancreatic cancer	6.09e-05	0.0006	CcSEcCtD
Pemetrexed—Leukopenia—Docetaxel—pancreatic cancer	6.09e-05	0.000599	CcSEcCtD
Pemetrexed—Body temperature increased—Fluorouracil—pancreatic cancer	6.08e-05	0.000598	CcSEcCtD
Pemetrexed—GART—Metabolism—STK11—pancreatic cancer	6.05e-05	0.00136	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—SLC2A2—pancreatic cancer	6.01e-05	0.00135	CbGpPWpGaD
Pemetrexed—Loss of consciousness—Docetaxel—pancreatic cancer	5.98e-05	0.000588	CcSEcCtD
Pemetrexed—Pancreatitis—Doxorubicin—pancreatic cancer	5.97e-05	0.000588	CcSEcCtD
Pemetrexed—Angina pectoris—Doxorubicin—pancreatic cancer	5.93e-05	0.000584	CcSEcCtD
Pemetrexed—Hypersensitivity—Irinotecan—pancreatic cancer	5.91e-05	0.000582	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle—FOXM1—pancreatic cancer	5.87e-05	0.00132	CbGpPWpGaD
Pemetrexed—Hypertension—Docetaxel—pancreatic cancer	5.87e-05	0.000578	CcSEcCtD
Pemetrexed—Infestation NOS—Epirubicin—pancreatic cancer	5.87e-05	0.000578	CcSEcCtD
Pemetrexed—Infestation—Epirubicin—pancreatic cancer	5.87e-05	0.000578	CcSEcCtD
Pemetrexed—Stevens-Johnson syndrome—Epirubicin—pancreatic cancer	5.82e-05	0.000573	CcSEcCtD
Pemetrexed—Arthralgia—Docetaxel—pancreatic cancer	5.79e-05	0.00057	CcSEcCtD
Pemetrexed—Myalgia—Docetaxel—pancreatic cancer	5.79e-05	0.00057	CcSEcCtD
Pemetrexed—Chest pain—Docetaxel—pancreatic cancer	5.79e-05	0.00057	CcSEcCtD
Pemetrexed—Nausea—Sunitinib—pancreatic cancer	5.79e-05	0.00057	CcSEcCtD
Pemetrexed—Pancytopenia—Doxorubicin—pancreatic cancer	5.78e-05	0.000569	CcSEcCtD
Pemetrexed—Renal failure—Epirubicin—pancreatic cancer	5.77e-05	0.000568	CcSEcCtD
Pemetrexed—Asthenia—Irinotecan—pancreatic cancer	5.76e-05	0.000567	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Epirubicin—pancreatic cancer	5.75e-05	0.000566	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—pancreatic cancer	5.75e-05	0.000566	CcSEcCtD
Pemetrexed—Stomatitis—Epirubicin—pancreatic cancer	5.72e-05	0.000563	CcSEcCtD
Pemetrexed—SLC46A1—Disease—JAG2—pancreatic cancer	5.71e-05	0.00128	CbGpPWpGaD
Pemetrexed—Conjunctivitis—Epirubicin—pancreatic cancer	5.7e-05	0.000562	CcSEcCtD
Pemetrexed—Neutropenia—Doxorubicin—pancreatic cancer	5.69e-05	0.000561	CcSEcCtD
Pemetrexed—Hypersensitivity—Fluorouracil—pancreatic cancer	5.66e-05	0.000558	CcSEcCtD
Pemetrexed—SLC46A1—Disease—MEN1—pancreatic cancer	5.63e-05	0.00127	CbGpPWpGaD
Pemetrexed—Asthenia—Gemcitabine—pancreatic cancer	5.61e-05	0.000552	CcSEcCtD
Pemetrexed—SLC46A1—Disease—SLC2A2—pancreatic cancer	5.59e-05	0.00126	CbGpPWpGaD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—CDKN2A—pancreatic cancer	5.56e-05	0.00125	CbGpPWpGaD
Pemetrexed—Hepatobiliary disease—Epirubicin—pancreatic cancer	5.55e-05	0.000547	CcSEcCtD
Pemetrexed—Oedema—Docetaxel—pancreatic cancer	5.55e-05	0.000546	CcSEcCtD
Pemetrexed—Anaphylactic shock—Docetaxel—pancreatic cancer	5.55e-05	0.000546	CcSEcCtD
Pemetrexed—Pruritus—Gemcitabine—pancreatic cancer	5.53e-05	0.000545	CcSEcCtD
Pemetrexed—Infection—Docetaxel—pancreatic cancer	5.51e-05	0.000543	CcSEcCtD
Pemetrexed—Diarrhoea—Irinotecan—pancreatic cancer	5.49e-05	0.000541	CcSEcCtD
Pemetrexed—Agranulocytosis—Epirubicin—pancreatic cancer	5.48e-05	0.000539	CcSEcCtD
Pemetrexed—DCK—Metabolism—PRSS1—pancreatic cancer	5.47e-05	0.00123	CbGpPWpGaD
Pemetrexed—Shock—Docetaxel—pancreatic cancer	5.46e-05	0.000538	CcSEcCtD
Pemetrexed—Nervous system disorder—Docetaxel—pancreatic cancer	5.44e-05	0.000536	CcSEcCtD
Pemetrexed—Pruritus—Fluorouracil—pancreatic cancer	5.44e-05	0.000536	CcSEcCtD
Pemetrexed—Thrombocytopenia—Docetaxel—pancreatic cancer	5.43e-05	0.000535	CcSEcCtD
Pemetrexed—Infestation NOS—Doxorubicin—pancreatic cancer	5.43e-05	0.000535	CcSEcCtD
Pemetrexed—Infestation—Doxorubicin—pancreatic cancer	5.43e-05	0.000535	CcSEcCtD
Pemetrexed—Skin disorder—Docetaxel—pancreatic cancer	5.39e-05	0.000531	CcSEcCtD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—CCND1—pancreatic cancer	5.38e-05	0.00121	CbGpPWpGaD
Pemetrexed—Stevens-Johnson syndrome—Doxorubicin—pancreatic cancer	5.38e-05	0.00053	CcSEcCtD
Pemetrexed—SLC46A1—Disease—SHH—pancreatic cancer	5.37e-05	0.00121	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—NFKBIA—pancreatic cancer	5.36e-05	0.00121	CbGpPWpGaD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—MYC—pancreatic cancer	5.36e-05	0.00121	CbGpPWpGaD
Pemetrexed—Diarrhoea—Gemcitabine—pancreatic cancer	5.35e-05	0.000527	CcSEcCtD
Pemetrexed—Renal failure—Doxorubicin—pancreatic cancer	5.34e-05	0.000526	CcSEcCtD
Pemetrexed—Neuropathy peripheral—Doxorubicin—pancreatic cancer	5.32e-05	0.000524	CcSEcCtD
Pemetrexed—Dizziness—Irinotecan—pancreatic cancer	5.31e-05	0.000523	CcSEcCtD
Pemetrexed—SLC46A1—Disease—IAPP—pancreatic cancer	5.3e-05	0.00119	CbGpPWpGaD
Pemetrexed—Stomatitis—Doxorubicin—pancreatic cancer	5.29e-05	0.000521	CcSEcCtD
Pemetrexed—Anorexia—Docetaxel—pancreatic cancer	5.29e-05	0.000521	CcSEcCtD
Pemetrexed—Conjunctivitis—Doxorubicin—pancreatic cancer	5.28e-05	0.00052	CcSEcCtD
Pemetrexed—Hepatitis—Epirubicin—pancreatic cancer	5.27e-05	0.000519	CcSEcCtD
Pemetrexed—Diarrhoea—Fluorouracil—pancreatic cancer	5.26e-05	0.000518	CcSEcCtD
Pemetrexed—DHFR—Disease—PRSS1—pancreatic cancer	5.25e-05	0.00118	CbGpPWpGaD
Pemetrexed—DHFR—Disease—ZNRF3—pancreatic cancer	5.25e-05	0.00118	CbGpPWpGaD
Pemetrexed—Pharyngitis—Epirubicin—pancreatic cancer	5.23e-05	0.000515	CcSEcCtD
Pemetrexed—GART—Metabolism—TYMS—pancreatic cancer	5.2e-05	0.00117	CbGpPWpGaD
Pemetrexed—Urinary tract disorder—Epirubicin—pancreatic cancer	5.2e-05	0.000512	CcSEcCtD
Pemetrexed—Urethral disorder—Epirubicin—pancreatic cancer	5.16e-05	0.000508	CcSEcCtD
Pemetrexed—Hepatobiliary disease—Doxorubicin—pancreatic cancer	5.13e-05	0.000506	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—EGF—pancreatic cancer	5.13e-05	0.00115	CbGpPWpGaD
Pemetrexed—DHFR—G1/S Transition—MYC—pancreatic cancer	5.13e-05	0.00115	CbGpPWpGaD
Pemetrexed—Vomiting—Irinotecan—pancreatic cancer	5.1e-05	0.000503	CcSEcCtD
Pemetrexed—SLC46A1—Disease—HSPA1B—pancreatic cancer	5.09e-05	0.00115	CbGpPWpGaD
Pemetrexed—Dizziness—Fluorouracil—pancreatic cancer	5.08e-05	0.000501	CcSEcCtD
Pemetrexed—Agranulocytosis—Doxorubicin—pancreatic cancer	5.07e-05	0.000499	CcSEcCtD
Pemetrexed—Rash—Irinotecan—pancreatic cancer	5.06e-05	0.000498	CcSEcCtD
Pemetrexed—Dermatitis—Irinotecan—pancreatic cancer	5.06e-05	0.000498	CcSEcCtD
Pemetrexed—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	5.05e-05	0.000498	CcSEcCtD
Pemetrexed—DHFR—Retinoblastoma (RB) in Cancer—TP53—pancreatic cancer	5.04e-05	0.00113	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—GLP1R—pancreatic cancer	5.01e-05	0.00113	CbGpPWpGaD
Pemetrexed—Erythema multiforme—Epirubicin—pancreatic cancer	4.98e-05	0.00049	CcSEcCtD
Pemetrexed—Vomiting—Gemcitabine—pancreatic cancer	4.97e-05	0.00049	CcSEcCtD
Pemetrexed—Dyspnoea—Docetaxel—pancreatic cancer	4.95e-05	0.000487	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—DPYD—pancreatic cancer	4.93e-05	0.00111	CbGpPWpGaD
Pemetrexed—Rash—Gemcitabine—pancreatic cancer	4.93e-05	0.000485	CcSEcCtD
Pemetrexed—Dermatitis—Gemcitabine—pancreatic cancer	4.93e-05	0.000485	CcSEcCtD
Pemetrexed—Eye disorder—Epirubicin—pancreatic cancer	4.92e-05	0.000485	CcSEcCtD
Pemetrexed—Vomiting—Fluorouracil—pancreatic cancer	4.89e-05	0.000481	CcSEcCtD
Pemetrexed—Dyspepsia—Docetaxel—pancreatic cancer	4.88e-05	0.000481	CcSEcCtD
Pemetrexed—Hepatitis—Doxorubicin—pancreatic cancer	4.87e-05	0.00048	CcSEcCtD
Pemetrexed—Rash—Fluorouracil—pancreatic cancer	4.85e-05	0.000477	CcSEcCtD
Pemetrexed—Dermatitis—Fluorouracil—pancreatic cancer	4.84e-05	0.000477	CcSEcCtD
Pemetrexed—Pharyngitis—Doxorubicin—pancreatic cancer	4.84e-05	0.000476	CcSEcCtD
Pemetrexed—Decreased appetite—Docetaxel—pancreatic cancer	4.82e-05	0.000475	CcSEcCtD
Pemetrexed—Urinary tract disorder—Doxorubicin—pancreatic cancer	4.81e-05	0.000474	CcSEcCtD
Pemetrexed—TYMS—Circadian rythm related genes—PPARG—pancreatic cancer	4.81e-05	0.00108	CbGpPWpGaD
Pemetrexed—Gastrointestinal disorder—Docetaxel—pancreatic cancer	4.79e-05	0.000472	CcSEcCtD
Pemetrexed—Fatigue—Docetaxel—pancreatic cancer	4.78e-05	0.000471	CcSEcCtD
Pemetrexed—Urethral disorder—Doxorubicin—pancreatic cancer	4.78e-05	0.000471	CcSEcCtD
Pemetrexed—Nausea—Irinotecan—pancreatic cancer	4.77e-05	0.000469	CcSEcCtD
Pemetrexed—DHFR—Disease—DTX1—pancreatic cancer	4.75e-05	0.00107	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—ARG2—pancreatic cancer	4.75e-05	0.00107	CbGpPWpGaD
Pemetrexed—Pain—Docetaxel—pancreatic cancer	4.74e-05	0.000467	CcSEcCtD
Pemetrexed—Constipation—Docetaxel—pancreatic cancer	4.74e-05	0.000467	CcSEcCtD
Pemetrexed—Arrhythmia—Epirubicin—pancreatic cancer	4.71e-05	0.000463	CcSEcCtD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—CCND1—pancreatic cancer	4.7e-05	0.00106	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—SLC2A2—pancreatic cancer	4.68e-05	0.00105	CbGpPWpGaD
Pemetrexed—Alopecia—Epirubicin—pancreatic cancer	4.65e-05	0.000458	CcSEcCtD
Pemetrexed—ATIC—Metabolism—CD44—pancreatic cancer	4.65e-05	0.00105	CbGpPWpGaD
Pemetrexed—Nausea—Gemcitabine—pancreatic cancer	4.64e-05	0.000457	CcSEcCtD
Pemetrexed—Erythema multiforme—Doxorubicin—pancreatic cancer	4.61e-05	0.000454	CcSEcCtD
Pemetrexed—Erythema—Epirubicin—pancreatic cancer	4.59e-05	0.000452	CcSEcCtD
Pemetrexed—Malnutrition—Epirubicin—pancreatic cancer	4.59e-05	0.000452	CcSEcCtD
Pemetrexed—Nausea—Fluorouracil—pancreatic cancer	4.57e-05	0.00045	CcSEcCtD
Pemetrexed—SLC46A1—Disease—JAG1—pancreatic cancer	4.56e-05	0.00103	CbGpPWpGaD
Pemetrexed—Eye disorder—Doxorubicin—pancreatic cancer	4.55e-05	0.000449	CcSEcCtD
Pemetrexed—Gastrointestinal pain—Docetaxel—pancreatic cancer	4.54e-05	0.000447	CcSEcCtD
Pemetrexed—Dysgeusia—Epirubicin—pancreatic cancer	4.49e-05	0.000442	CcSEcCtD
Pemetrexed—TYMS—G1/S Transition—MYC—pancreatic cancer	4.47e-05	0.00101	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—GCG—pancreatic cancer	4.46e-05	0.001	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PRSS1—pancreatic cancer	4.4e-05	0.00099	CbGpPWpGaD
Pemetrexed—TYMS—Retinoblastoma (RB) in Cancer—TP53—pancreatic cancer	4.4e-05	0.00099	CbGpPWpGaD
Pemetrexed—Abdominal pain—Docetaxel—pancreatic cancer	4.39e-05	0.000432	CcSEcCtD
Pemetrexed—Body temperature increased—Docetaxel—pancreatic cancer	4.39e-05	0.000432	CcSEcCtD
Pemetrexed—Arrhythmia—Doxorubicin—pancreatic cancer	4.35e-05	0.000429	CcSEcCtD
Pemetrexed—SLC46A1—Disease—CD44—pancreatic cancer	4.33e-05	0.000974	CbGpPWpGaD
Pemetrexed—DHFR—Mitotic G1-G1/S phases—MYC—pancreatic cancer	4.32e-05	0.000972	CbGpPWpGaD
Pemetrexed—Alopecia—Doxorubicin—pancreatic cancer	4.31e-05	0.000424	CcSEcCtD
Pemetrexed—SLC46A1—Disease—HSPA1A—pancreatic cancer	4.3e-05	0.000967	CbGpPWpGaD
Pemetrexed—Malnutrition—Doxorubicin—pancreatic cancer	4.24e-05	0.000418	CcSEcCtD
Pemetrexed—Erythema—Doxorubicin—pancreatic cancer	4.24e-05	0.000418	CcSEcCtD
Pemetrexed—Anaemia—Epirubicin—pancreatic cancer	4.24e-05	0.000417	CcSEcCtD
Pemetrexed—GART—Metabolism—APOE—pancreatic cancer	4.23e-05	0.000952	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—STK11—pancreatic cancer	4.19e-05	0.000944	CbGpPWpGaD
Pemetrexed—Dysgeusia—Doxorubicin—pancreatic cancer	4.15e-05	0.000409	CcSEcCtD
Pemetrexed—DCK—Metabolism—TYMP—pancreatic cancer	4.15e-05	0.000934	CbGpPWpGaD
Pemetrexed—Syncope—Epirubicin—pancreatic cancer	4.11e-05	0.000405	CcSEcCtD
Pemetrexed—Leukopenia—Epirubicin—pancreatic cancer	4.1e-05	0.000404	CcSEcCtD
Pemetrexed—Hypersensitivity—Docetaxel—pancreatic cancer	4.09e-05	0.000403	CcSEcCtD
Pemetrexed—Loss of consciousness—Epirubicin—pancreatic cancer	4.03e-05	0.000397	CcSEcCtD
Pemetrexed—DHFR—Disease—DTX4—pancreatic cancer	3.98e-05	0.000896	CbGpPWpGaD
Pemetrexed—Asthenia—Docetaxel—pancreatic cancer	3.98e-05	0.000392	CcSEcCtD
Pemetrexed—Hypertension—Epirubicin—pancreatic cancer	3.96e-05	0.00039	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—PTGS2—pancreatic cancer	3.94e-05	0.000887	CbGpPWpGaD
Pemetrexed—Pruritus—Docetaxel—pancreatic cancer	3.93e-05	0.000387	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle, Mitotic—TYMS—pancreatic cancer	3.92e-05	0.000883	CbGpPWpGaD
Pemetrexed—Anaemia—Doxorubicin—pancreatic cancer	3.92e-05	0.000386	CcSEcCtD
Pemetrexed—Chest pain—Epirubicin—pancreatic cancer	3.9e-05	0.000384	CcSEcCtD
Pemetrexed—Myalgia—Epirubicin—pancreatic cancer	3.9e-05	0.000384	CcSEcCtD
Pemetrexed—Arthralgia—Epirubicin—pancreatic cancer	3.9e-05	0.000384	CcSEcCtD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—pancreatic cancer	3.88e-05	0.000382	CcSEcCtD
Pemetrexed—DHFR—Disease—PPP2R5B—pancreatic cancer	3.87e-05	0.000872	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PRSS1—pancreatic cancer	3.84e-05	0.000864	CbGpPWpGaD
Pemetrexed—GART—Metabolism—PIK3CG—pancreatic cancer	3.82e-05	0.000859	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—ARG2—pancreatic cancer	3.81e-05	0.000858	CbGpPWpGaD
Pemetrexed—Syncope—Doxorubicin—pancreatic cancer	3.8e-05	0.000375	CcSEcCtD
Pemetrexed—Leukopenia—Doxorubicin—pancreatic cancer	3.8e-05	0.000374	CcSEcCtD
Pemetrexed—Diarrhoea—Docetaxel—pancreatic cancer	3.8e-05	0.000374	CcSEcCtD
Pemetrexed—TYMS—Mitotic G1-G1/S phases—MYC—pancreatic cancer	3.77e-05	0.000848	CbGpPWpGaD
Pemetrexed—Oedema—Epirubicin—pancreatic cancer	3.74e-05	0.000369	CcSEcCtD
Pemetrexed—Anaphylactic shock—Epirubicin—pancreatic cancer	3.74e-05	0.000369	CcSEcCtD
Pemetrexed—Loss of consciousness—Doxorubicin—pancreatic cancer	3.73e-05	0.000367	CcSEcCtD
Pemetrexed—DHFR—Disease—HEY2—pancreatic cancer	3.73e-05	0.000839	CbGpPWpGaD
Pemetrexed—Infection—Epirubicin—pancreatic cancer	3.72e-05	0.000366	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—BRCA2—pancreatic cancer	3.69e-05	0.00083	CbGpPWpGaD
Pemetrexed—GART—Metabolism—PPARG—pancreatic cancer	3.69e-05	0.000829	CbGpPWpGaD
Pemetrexed—Shock—Epirubicin—pancreatic cancer	3.68e-05	0.000363	CcSEcCtD
Pemetrexed—Nervous system disorder—Epirubicin—pancreatic cancer	3.67e-05	0.000361	CcSEcCtD
Pemetrexed—Dizziness—Docetaxel—pancreatic cancer	3.67e-05	0.000361	CcSEcCtD
Pemetrexed—Thrombocytopenia—Epirubicin—pancreatic cancer	3.66e-05	0.000361	CcSEcCtD
Pemetrexed—Hypertension—Doxorubicin—pancreatic cancer	3.66e-05	0.000361	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CASP3—pancreatic cancer	3.66e-05	0.000823	CbGpPWpGaD
Pemetrexed—Skin disorder—Epirubicin—pancreatic cancer	3.63e-05	0.000358	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—CD44—pancreatic cancer	3.62e-05	0.000815	CbGpPWpGaD
Pemetrexed—Chest pain—Doxorubicin—pancreatic cancer	3.61e-05	0.000356	CcSEcCtD
Pemetrexed—Arthralgia—Doxorubicin—pancreatic cancer	3.61e-05	0.000356	CcSEcCtD
Pemetrexed—Myalgia—Doxorubicin—pancreatic cancer	3.61e-05	0.000356	CcSEcCtD
Pemetrexed—ATIC—Metabolism—TYMS—pancreatic cancer	3.61e-05	0.000812	CbGpPWpGaD
Pemetrexed—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—pancreatic cancer	3.59e-05	0.000353	CcSEcCtD
Pemetrexed—Anorexia—Epirubicin—pancreatic cancer	3.57e-05	0.000351	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CCND1—pancreatic cancer	3.56e-05	0.000801	CbGpPWpGaD
Pemetrexed—Vomiting—Docetaxel—pancreatic cancer	3.53e-05	0.000347	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—CTNNB1—pancreatic cancer	3.53e-05	0.000793	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—TYMS—pancreatic cancer	3.51e-05	0.000789	CbGpPWpGaD
Pemetrexed—Rash—Docetaxel—pancreatic cancer	3.5e-05	0.000345	CcSEcCtD
Pemetrexed—Dermatitis—Docetaxel—pancreatic cancer	3.5e-05	0.000344	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—GCG—pancreatic cancer	3.47e-05	0.000782	CbGpPWpGaD
Pemetrexed—Oedema—Doxorubicin—pancreatic cancer	3.46e-05	0.000341	CcSEcCtD
Pemetrexed—Anaphylactic shock—Doxorubicin—pancreatic cancer	3.46e-05	0.000341	CcSEcCtD
Pemetrexed—DHFR—Disease—HEY1—pancreatic cancer	3.45e-05	0.000777	CbGpPWpGaD
Pemetrexed—Infection—Doxorubicin—pancreatic cancer	3.44e-05	0.000339	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—PTEN—pancreatic cancer	3.44e-05	0.000773	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—SMAD4—pancreatic cancer	3.42e-05	0.000769	CbGpPWpGaD
Pemetrexed—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	3.41e-05	0.000336	CcSEcCtD
Pemetrexed—Shock—Doxorubicin—pancreatic cancer	3.41e-05	0.000335	CcSEcCtD
Pemetrexed—Nervous system disorder—Doxorubicin—pancreatic cancer	3.4e-05	0.000334	CcSEcCtD
Pemetrexed—Thrombocytopenia—Doxorubicin—pancreatic cancer	3.39e-05	0.000334	CcSEcCtD
Pemetrexed—Skin disorder—Doxorubicin—pancreatic cancer	3.36e-05	0.000331	CcSEcCtD
Pemetrexed—GART—Metabolism—PIK3CD—pancreatic cancer	3.36e-05	0.000756	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GLP1R—pancreatic cancer	3.34e-05	0.000753	CbGpPWpGaD
Pemetrexed—Dyspnoea—Epirubicin—pancreatic cancer	3.34e-05	0.000329	CcSEcCtD
Pemetrexed—SLC46A1—Disease—HES1—pancreatic cancer	3.34e-05	0.000751	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—TYMP—pancreatic cancer	3.33e-05	0.00075	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—ARG2—pancreatic cancer	3.33e-05	0.000749	CbGpPWpGaD
Pemetrexed—Anorexia—Doxorubicin—pancreatic cancer	3.3e-05	0.000325	CcSEcCtD
Pemetrexed—TYMS—Circadian rythm related genes—PTEN—pancreatic cancer	3.3e-05	0.000742	CbGpPWpGaD
Pemetrexed—Nausea—Docetaxel—pancreatic cancer	3.3e-05	0.000325	CcSEcCtD
Pemetrexed—Dyspepsia—Epirubicin—pancreatic cancer	3.29e-05	0.000324	CcSEcCtD
Pemetrexed—DCK—Metabolism—DPYD—pancreatic cancer	3.29e-05	0.00074	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—STK11—pancreatic cancer	3.27e-05	0.000735	CbGpPWpGaD
Pemetrexed—Decreased appetite—Epirubicin—pancreatic cancer	3.25e-05	0.00032	CcSEcCtD
Pemetrexed—Gastrointestinal disorder—Epirubicin—pancreatic cancer	3.23e-05	0.000318	CcSEcCtD
Pemetrexed—Fatigue—Epirubicin—pancreatic cancer	3.23e-05	0.000318	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle—BRCA2—pancreatic cancer	3.22e-05	0.000724	CbGpPWpGaD
Pemetrexed—Pain—Epirubicin—pancreatic cancer	3.2e-05	0.000315	CcSEcCtD
Pemetrexed—Constipation—Epirubicin—pancreatic cancer	3.2e-05	0.000315	CcSEcCtD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—SRC—pancreatic cancer	3.19e-05	0.000717	CbGpPWpGaD
Pemetrexed—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	3.15e-05	0.000311	CcSEcCtD
Pemetrexed—DCK—Metabolism—SLC2A2—pancreatic cancer	3.12e-05	0.000703	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—VEGFA—pancreatic cancer	3.1e-05	0.000698	CbGpPWpGaD
Pemetrexed—Dyspnoea—Doxorubicin—pancreatic cancer	3.09e-05	0.000304	CcSEcCtD
Pemetrexed—DHFR—Disease—JAG2—pancreatic cancer	3.06e-05	0.000689	CbGpPWpGaD
Pemetrexed—Gastrointestinal pain—Epirubicin—pancreatic cancer	3.06e-05	0.000301	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—TERT—pancreatic cancer	3.06e-05	0.000687	CbGpPWpGaD
Pemetrexed—Dyspepsia—Doxorubicin—pancreatic cancer	3.05e-05	0.0003	CcSEcCtD
Pemetrexed—DHFR—Disease—MEN1—pancreatic cancer	3.02e-05	0.000679	CbGpPWpGaD
Pemetrexed—Decreased appetite—Doxorubicin—pancreatic cancer	3.01e-05	0.000296	CcSEcCtD
Pemetrexed—DHFR—Disease—SLC2A2—pancreatic cancer	3e-05	0.000674	CbGpPWpGaD
Pemetrexed—Gastrointestinal disorder—Doxorubicin—pancreatic cancer	2.99e-05	0.000294	CcSEcCtD
Pemetrexed—Fatigue—Doxorubicin—pancreatic cancer	2.99e-05	0.000294	CcSEcCtD
Pemetrexed—Urticaria—Epirubicin—pancreatic cancer	2.97e-05	0.000293	CcSEcCtD
Pemetrexed—Constipation—Doxorubicin—pancreatic cancer	2.96e-05	0.000292	CcSEcCtD
Pemetrexed—Pain—Doxorubicin—pancreatic cancer	2.96e-05	0.000292	CcSEcCtD
Pemetrexed—Abdominal pain—Epirubicin—pancreatic cancer	2.96e-05	0.000291	CcSEcCtD
Pemetrexed—Body temperature increased—Epirubicin—pancreatic cancer	2.96e-05	0.000291	CcSEcCtD
Pemetrexed—ATIC—Metabolism—APOE—pancreatic cancer	2.93e-05	0.00066	CbGpPWpGaD
Pemetrexed—GART—Metabolism—PIK3CB—pancreatic cancer	2.93e-05	0.000659	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—TERT—pancreatic cancer	2.92e-05	0.000658	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—TYMP—pancreatic cancer	2.91e-05	0.000655	CbGpPWpGaD
Pemetrexed—GART—Metabolism—PTGS2—pancreatic cancer	2.9e-05	0.000653	CbGpPWpGaD
Pemetrexed—DHFR—Disease—SHH—pancreatic cancer	2.88e-05	0.000648	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—MYC—pancreatic cancer	2.86e-05	0.000642	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—TGFB1—pancreatic cancer	2.85e-05	0.000641	CbGpPWpGaD
Pemetrexed—DHFR—Disease—IAPP—pancreatic cancer	2.84e-05	0.00064	CbGpPWpGaD
Pemetrexed—Gastrointestinal pain—Doxorubicin—pancreatic cancer	2.83e-05	0.000279	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—TYMS—pancreatic cancer	2.81e-05	0.000632	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—HIF1A—pancreatic cancer	2.8e-05	0.000629	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—EGFR—pancreatic cancer	2.79e-05	0.000628	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—TSC2—pancreatic cancer	2.79e-05	0.000627	CbGpPWpGaD
Pemetrexed—Hypersensitivity—Epirubicin—pancreatic cancer	2.76e-05	0.000272	CcSEcCtD
Pemetrexed—Urticaria—Doxorubicin—pancreatic cancer	2.75e-05	0.000271	CcSEcCtD
Pemetrexed—Body temperature increased—Doxorubicin—pancreatic cancer	2.74e-05	0.00027	CcSEcCtD
Pemetrexed—Abdominal pain—Doxorubicin—pancreatic cancer	2.74e-05	0.00027	CcSEcCtD
Pemetrexed—SLC46A1—Disease—APOE—pancreatic cancer	2.73e-05	0.000614	CbGpPWpGaD
Pemetrexed—DHFR—Disease—HSPA1B—pancreatic cancer	2.73e-05	0.000614	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GLP1R—pancreatic cancer	2.69e-05	0.000605	CbGpPWpGaD
Pemetrexed—Asthenia—Epirubicin—pancreatic cancer	2.68e-05	0.000264	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle—TERT—pancreatic cancer	2.67e-05	0.0006	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—TNF—pancreatic cancer	2.66e-05	0.000598	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—RB1—pancreatic cancer	2.66e-05	0.000598	CbGpPWpGaD
Pemetrexed—Pruritus—Epirubicin—pancreatic cancer	2.65e-05	0.000261	CcSEcCtD
Pemetrexed—ATIC—Metabolism—PIK3CG—pancreatic cancer	2.65e-05	0.000596	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—DPYD—pancreatic cancer	2.64e-05	0.000595	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—KRAS—pancreatic cancer	2.64e-05	0.000594	CbGpPWpGaD
Pemetrexed—Diarrhoea—Epirubicin—pancreatic cancer	2.56e-05	0.000252	CcSEcCtD
Pemetrexed—ATIC—Metabolism—PPARG—pancreatic cancer	2.56e-05	0.000575	CbGpPWpGaD
Pemetrexed—Hypersensitivity—Doxorubicin—pancreatic cancer	2.55e-05	0.000251	CcSEcCtD
Pemetrexed—GART—Metabolism—PTEN—pancreatic cancer	2.53e-05	0.000569	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—NOTCH1—pancreatic cancer	2.52e-05	0.000567	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—SLC2A2—pancreatic cancer	2.51e-05	0.000565	CbGpPWpGaD
Pemetrexed—Asthenia—Doxorubicin—pancreatic cancer	2.48e-05	0.000245	CcSEcCtD
Pemetrexed—Dizziness—Epirubicin—pancreatic cancer	2.47e-05	0.000244	CcSEcCtD
Pemetrexed—Pruritus—Doxorubicin—pancreatic cancer	2.45e-05	0.000241	CcSEcCtD
Pemetrexed—DHFR—Disease—JAG1—pancreatic cancer	2.44e-05	0.00055	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—EGF—pancreatic cancer	2.43e-05	0.000548	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—PIK3CA—pancreatic cancer	2.42e-05	0.000545	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—CD44—pancreatic cancer	2.42e-05	0.000544	CbGpPWpGaD
Pemetrexed—Vomiting—Epirubicin—pancreatic cancer	2.38e-05	0.000234	CcSEcCtD
Pemetrexed—DHFR—Cell Cycle—RB1—pancreatic cancer	2.38e-05	0.000535	CbGpPWpGaD
Pemetrexed—Diarrhoea—Doxorubicin—pancreatic cancer	2.37e-05	0.000233	CcSEcCtD
Pemetrexed—Rash—Epirubicin—pancreatic cancer	2.36e-05	0.000232	CcSEcCtD
Pemetrexed—Dermatitis—Epirubicin—pancreatic cancer	2.36e-05	0.000232	CcSEcCtD
Pemetrexed—TYMS—Metabolism—GLP1R—pancreatic cancer	2.35e-05	0.000528	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—TP53—pancreatic cancer	2.34e-05	0.000528	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CDKN2A—pancreatic cancer	2.34e-05	0.000526	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PIK3CD—pancreatic cancer	2.33e-05	0.000524	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—RB1—pancreatic cancer	2.32e-05	0.000522	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CD44—pancreatic cancer	2.32e-05	0.000522	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—GCG—pancreatic cancer	2.32e-05	0.000522	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—DPYD—pancreatic cancer	2.31e-05	0.000519	CbGpPWpGaD
Pemetrexed—DHFR—Disease—HSPA1A—pancreatic cancer	2.3e-05	0.000518	CbGpPWpGaD
Pemetrexed—Dizziness—Doxorubicin—pancreatic cancer	2.29e-05	0.000225	CcSEcCtD
Pemetrexed—SLC46A1—Metabolism—APOE—pancreatic cancer	2.29e-05	0.000514	CbGpPWpGaD
Pemetrexed—TYMS—Circadian rythm related genes—TP53—pancreatic cancer	2.25e-05	0.000507	CbGpPWpGaD
Pemetrexed—Nausea—Epirubicin—pancreatic cancer	2.22e-05	0.000219	CcSEcCtD
Pemetrexed—Vomiting—Doxorubicin—pancreatic cancer	2.2e-05	0.000217	CcSEcCtD
Pemetrexed—TYMS—Metabolism—SLC2A2—pancreatic cancer	2.19e-05	0.000493	CbGpPWpGaD
Pemetrexed—Rash—Doxorubicin—pancreatic cancer	2.18e-05	0.000215	CcSEcCtD
Pemetrexed—Dermatitis—Doxorubicin—pancreatic cancer	2.18e-05	0.000215	CcSEcCtD
Pemetrexed—DCK—Metabolism—STK11—pancreatic cancer	2.18e-05	0.00049	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PIK3CD—pancreatic cancer	2.16e-05	0.000487	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CDKN2A—pancreatic cancer	2.09e-05	0.00047	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—RB1—pancreatic cancer	2.07e-05	0.000467	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PIK3CG—pancreatic cancer	2.06e-05	0.000464	CbGpPWpGaD
Pemetrexed—Nausea—Doxorubicin—pancreatic cancer	2.06e-05	0.000203	CcSEcCtD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CDKN2A—pancreatic cancer	2.04e-05	0.000459	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PIK3CB—pancreatic cancer	2.03e-05	0.000456	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PTGS2—pancreatic cancer	2.01e-05	0.000452	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PPARG—pancreatic cancer	1.99e-05	0.000448	CbGpPWpGaD
Pemetrexed—TYMS—Integrated Pancreatic Cancer Pathway—AKT1—pancreatic cancer	1.98e-05	0.000446	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—CCND1—pancreatic cancer	1.97e-05	0.000444	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—CD44—pancreatic cancer	1.94e-05	0.000437	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PIK3CB—pancreatic cancer	1.89e-05	0.000425	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—TYMS—pancreatic cancer	1.87e-05	0.000422	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PTGS2—pancreatic cancer	1.87e-05	0.000421	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—GCG—pancreatic cancer	1.86e-05	0.000419	CbGpPWpGaD
Pemetrexed—DHFR—Disease—SMAD4—pancreatic cancer	1.83e-05	0.000412	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CDKN2A—pancreatic cancer	1.82e-05	0.00041	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PIK3CD—pancreatic cancer	1.81e-05	0.000408	CbGpPWpGaD
Pemetrexed—DHFR—Disease—HES1—pancreatic cancer	1.79e-05	0.000402	CbGpPWpGaD
Pemetrexed—GART—Metabolism—PIK3CA—pancreatic cancer	1.78e-05	0.000401	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—CCND1—pancreatic cancer	1.77e-05	0.000397	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PTEN—pancreatic cancer	1.75e-05	0.000394	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—STK11—pancreatic cancer	1.75e-05	0.000394	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—CCND1—pancreatic cancer	1.72e-05	0.000388	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—CD44—pancreatic cancer	1.7e-05	0.000382	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—CTNNB1—pancreatic cancer	1.67e-05	0.000376	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PTEN—pancreatic cancer	1.63e-05	0.000367	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—GCG—pancreatic cancer	1.63e-05	0.000366	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle, Mitotic—MYC—pancreatic cancer	1.58e-05	0.000356	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PIK3CB—pancreatic cancer	1.58e-05	0.000356	CbGpPWpGaD
Pemetrexed—DHFR—Disease—TERT—pancreatic cancer	1.57e-05	0.000353	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PTGS2—pancreatic cancer	1.57e-05	0.000352	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—CCND1—pancreatic cancer	1.54e-05	0.000347	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—STK11—pancreatic cancer	1.53e-05	0.000344	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—APOE—pancreatic cancer	1.52e-05	0.000343	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—SRC—pancreatic cancer	1.51e-05	0.00034	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—TYMS—pancreatic cancer	1.51e-05	0.000339	CbGpPWpGaD
Pemetrexed—DHFR—Disease—HIF1A—pancreatic cancer	1.5e-05	0.000337	CbGpPWpGaD
Pemetrexed—DHFR—Disease—TSC2—pancreatic cancer	1.5e-05	0.000336	CbGpPWpGaD
Pemetrexed—DHFR—Disease—APOE—pancreatic cancer	1.46e-05	0.000329	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—STAT3—pancreatic cancer	1.46e-05	0.000328	CbGpPWpGaD
Pemetrexed—GART—Metabolism—AKT1—pancreatic cancer	1.46e-05	0.000328	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—NRAS—pancreatic cancer	1.45e-05	0.000327	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—MYC—pancreatic cancer	1.42e-05	0.000319	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle, Mitotic—MYC—pancreatic cancer	1.38e-05	0.000311	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PIK3CG—pancreatic cancer	1.38e-05	0.00031	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PTEN—pancreatic cancer	1.37e-05	0.000307	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—MYC—pancreatic cancer	1.36e-05	0.000305	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—TGFB1—pancreatic cancer	1.35e-05	0.000304	CbGpPWpGaD
Pemetrexed—DHFR—Disease—NOTCH1—pancreatic cancer	1.35e-05	0.000304	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PPARG—pancreatic cancer	1.33e-05	0.000299	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—EGFR—pancreatic cancer	1.33e-05	0.000298	CbGpPWpGaD
Pemetrexed—DHFR—Disease—EGF—pancreatic cancer	1.31e-05	0.000294	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—KRAS—pancreatic cancer	1.25e-05	0.000282	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—PIK3CA—pancreatic cancer	1.24e-05	0.000278	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—MYC—pancreatic cancer	1.24e-05	0.000278	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—APOE—pancreatic cancer	1.23e-05	0.000276	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PIK3CD—pancreatic cancer	1.21e-05	0.000272	CbGpPWpGaD
Pemetrexed—DHFR—Cell Cycle—TP53—pancreatic cancer	1.16e-05	0.000262	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PIK3CD—pancreatic cancer	1.16e-05	0.000261	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—PIK3CA—pancreatic cancer	1.15e-05	0.000259	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PIK3CG—pancreatic cancer	1.11e-05	0.000249	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—APOE—pancreatic cancer	1.07e-05	0.000241	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PPARG—pancreatic cancer	1.07e-05	0.00024	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—HRAS—pancreatic cancer	1.06e-05	0.000239	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PIK3CB—pancreatic cancer	1.05e-05	0.000237	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PTGS2—pancreatic cancer	1.04e-05	0.000235	CbGpPWpGaD
Pemetrexed—TYMS—Cell Cycle—TP53—pancreatic cancer	1.01e-05	0.000228	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PIK3CB—pancreatic cancer	1.01e-05	0.000228	CbGpPWpGaD
Pemetrexed—ATIC—Metabolism—AKT1—pancreatic cancer	1.01e-05	0.000227	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PTGS2—pancreatic cancer	1e-05	0.000226	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PIK3CD—pancreatic cancer	9.72e-06	0.000219	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PIK3CG—pancreatic cancer	9.65e-06	0.000217	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—PIK3CA—pancreatic cancer	9.63e-06	0.000217	CbGpPWpGaD
Pemetrexed—SLC46A1—Disease—AKT1—pancreatic cancer	9.4e-06	0.000211	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PPARG—pancreatic cancer	9.31e-06	0.00021	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PTEN—pancreatic cancer	9.11e-06	0.000205	CbGpPWpGaD
Pemetrexed—DHFR—Disease—CTNNB1—pancreatic cancer	8.97e-06	0.000202	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PTEN—pancreatic cancer	8.74e-06	0.000197	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PIK3CD—pancreatic cancer	8.48e-06	0.000191	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PIK3CB—pancreatic cancer	8.47e-06	0.000191	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PTGS2—pancreatic cancer	8.4e-06	0.000189	CbGpPWpGaD
Pemetrexed—DHFR—Disease—SRC—pancreatic cancer	8.11e-06	0.000182	CbGpPWpGaD
Pemetrexed—SLC46A1—Metabolism—AKT1—pancreatic cancer	7.87e-06	0.000177	CbGpPWpGaD
Pemetrexed—DHFR—Disease—STAT3—pancreatic cancer	7.82e-06	0.000176	CbGpPWpGaD
Pemetrexed—DHFR—Disease—NRAS—pancreatic cancer	7.8e-06	0.000176	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PIK3CB—pancreatic cancer	7.39e-06	0.000166	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PTGS2—pancreatic cancer	7.33e-06	0.000165	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PTEN—pancreatic cancer	7.32e-06	0.000165	CbGpPWpGaD
Pemetrexed—DHFR—Disease—MYC—pancreatic cancer	7.27e-06	0.000164	CbGpPWpGaD
Pemetrexed—DHFR—Disease—TGFB1—pancreatic cancer	7.25e-06	0.000163	CbGpPWpGaD
Pemetrexed—DHFR—Disease—EGFR—pancreatic cancer	7.11e-06	0.00016	CbGpPWpGaD
Pemetrexed—DHFR—Disease—KRAS—pancreatic cancer	6.71e-06	0.000151	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—PIK3CA—pancreatic cancer	6.43e-06	0.000145	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PTEN—pancreatic cancer	6.39e-06	0.000144	CbGpPWpGaD
Pemetrexed—DHFR—Disease—PIK3CA—pancreatic cancer	6.17e-06	0.000139	CbGpPWpGaD
Pemetrexed—DHFR—Disease—HRAS—pancreatic cancer	5.71e-06	0.000128	CbGpPWpGaD
Pemetrexed—DCK—Metabolism—AKT1—pancreatic cancer	5.25e-06	0.000118	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—PIK3CA—pancreatic cancer	5.17e-06	0.000116	CbGpPWpGaD
Pemetrexed—DHFR—Disease—AKT1—pancreatic cancer	5.04e-06	0.000113	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—PIK3CA—pancreatic cancer	4.51e-06	0.000101	CbGpPWpGaD
Pemetrexed—DHFR—Metabolism—AKT1—pancreatic cancer	4.22e-06	9.5e-05	CbGpPWpGaD
Pemetrexed—TYMS—Metabolism—AKT1—pancreatic cancer	3.68e-06	8.29e-05	CbGpPWpGaD
